U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548996) titled 'Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes' on April 14.
Brief Summary: This is a non-randomized, parallel-controlled, single-center, open-label clinical trial designed to evaluate the efficacy of dimethyl fumarate in preserving pancreatic beta-cell function in adults with type 1 diabetes, as well as its safety and tolerability in this population.
Eligible participants are adults aged 18 to 65 years who meet the ADA 2024 diagnostic criteria for type 1 diabetes, have at least 2 positive islet autoantibodies, and have residual beta-cell function as evidenced by a random C-peptide level of at least 200 pmol/...